• Skip to main content
  • Skip to footer

Akari Therapeutics

A Revolution in Treating Autoinflammatory & Orphan Diseases

Menu
  • HOME
  • ABOUT
    • Close
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
  • AREAS OF FOCUS
    • Close
    • PIPELINE
    • POSTERS & PUBLICATIONS
    • LEGACY PIPELINE ASSETS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • GENERAL MEETING OF SHAREHOLDERS
      • Close
      • GENERAL MEETING
      • ANNUAL GENERAL MEETING
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & PRESENTATIONS
      • Close
      • PRESS RELEASES
      • PRESENTATIONS
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • STORIES
  • CONTACT US

Press Release

Akari TX / May 16, 2024

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

BOSTON and LONDON, May 16, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for …

[Read more...] about Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Akari TX / May 1, 2024

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune …

[Read more...] about Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

Akari TX / May 1, 2024

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today …

[Read more...] about Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Akari TX / April 15, 2024

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 

BOSTON and LONDON, March 15, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for …

[Read more...] about Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 

Akari TX / March 5, 2024

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

BOSTON, MA and PLEASANTON, CA – March 5, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …

[Read more...] about Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

« Previous Page
Next Page »

Footer

Follow Us

Terms of Use
Privacy Statement
Contact Us

Akari TX

Copyright © 2025 · Akari Therapeutics · Site Designed by Polus Digital, Inc.